Last updated: February 20, 2026
What is the scope of patent EP3429559?
EP3429559 claims a pharmaceutical compound, specifically a class of 2-aminopyridine derivatives. The patent covers compounds with specific chemical substituents designed for kinase inhibition, particularly targeting a particular enzyme subclass involved in oncogenic pathways.
The patent’s scope encompasses:
- Chemical compositions: 2-aminopyridine derivatives with defined substitutions at multiple positions.
- Methods of production: Synthesis protocols for the claimed compounds.
- Method of use: Treatment of diseases associated with kinase activity, notably cancers.
- Pharmaceutical formulations: Including doses and delivery methods.
The scope is broad within the chemical class but is limited to compounds with the defined substituents and specific kinase targets.
How are the claims structured?
Independent claims
- Claim 1: Defines a compound characterized by a core 2-aminopyridine structure with substituents R1 through R4, where R1-R4 are selected from specified groups. It sets the general scope for any compound conforming to this structure.
- Claim 2: Specifies a subset with particular substituents R1 and R2, narrowing the scope to a specific compound or class.
- Claim 3: Covers pharmaceutical compositions containing the compounds from claims 1 or 2.
- Claim 4: Details a method of inhibiting kinase activity by administering the claimed compounds.
Dependent claims
Dependent claims further specify particular substituents, methods, or formulations, narrowing the scope from the independent claims but potentially increasing enforceability and definitional clarity.
Key points
- The patent provides a flexible scaffold targeting kinase enzymes implicated in diseases.
- Claims are centered on chemical structure, synthesis, use, and formulations, providing multiple layers of protection.
- The scope aims to safeguard a chemical class with therapeutic potential, not a single molecule.
How does the patent landscape look for this class of compounds?
Precedent patents
- Multiple patents have protected kinase inhibitors, especially within the 2-aminopyridine scaffold.
- Patent families from companies like Novartis, AstraZeneca, and Pfizer target kinase inhibitors with similar structures.
- Many earlier patents focus on the same core but vary substituents, leading to a crowded landscape.
Recent filings
- A surge in filings over the last five years reflects ongoing interest in kinase inhibitor development.
- Many filings focus on specific substituents to avoid prior art and carve out novel niches.
Competitive status
- EP3429559 appears to claim a broader chemical space than many prior patents but overlaps with known kinase inhibitor patents.
- Patent families often contain corresponding applications or granted patents internationally, indicating strategic filings.
Legal status
- As of the latest data, EP3429559 remains granted with no opposition filed.
- Its claim set has not been challenged publicly, but potential for patent opposition exists given the overlapping landscape.
How does EP3429559 integrate into existing patent strategies?
- The patent can block generic entry for compounds within the defined scope.
- It may serve as a basis for licensing or collaboration, given broad claims.
- The patent's lifespan extends until approximately 2040, assuming standard 20-year term from filing.
Summary table of key patent data
| Parameter |
Details |
| Filing date |
August 21, 2018 |
| Priority date |
August 21, 2017 |
| Publication number |
EP3429559 B1 |
| Grant status |
Granted |
| Patent family coverage |
Europe, US, China, Japan, Canada |
| Cited art reference |
Numerous kinase inhibitor patents, e.g., US9, Real-time patent landscape analysis suggests competition from similar structural scaffolds, which could impact enforceability and market exclusivity. |
Key Takeaways
- EP3429559 claims a broad chemical scaffold of kinase inhibitors, focusing on 2-aminopyridine derivatives.
- The patent's claims cover compounds, methods, and formulations relevant for targeted cancer therapy.
- Its landscape overlaps significantly with existing kinase inhibitor patents, indicating a competitive environment.
- The patent remains in force and can influence licensing discussions and market entry strategies.
- Developers should analyze overlapping patents to evaluate freedom to operate, especially in rapidly evolving kinase inhibitor areas.
FAQs
1. How does EP3429559 compare to earlier kinase inhibitor patents?
It broadens the chemical scope within the 2-aminopyridine class but overlaps with prior art, requiring detailed freedom-to-operate analysis.
2. What are key elements in patent claim validity for compounds like these?
Novelty and inventive step depend on specific substituents and their unexpected therapeutic effects beyond known kinase inhibitors.
3. Which jurisdictions are most relevant for enforcing EP3429559?
Europe, the US, China, and Japan are strategic markets, with patent rights enforceable within those jurisdictions.
4. Can this patent block generic versions of similar kinase inhibitors?
Yes, if the generic compounds fall within the scope of the claims, the patent can serve as an effective barrier.
5. What future patent filings could impact this patent's value?
Further filings with narrower claims, or opposition proceedings, could influence the patent’s enforceability or scope.
References
[1] European Patent Office. (2023). Patent EP3429559.
[2] WIPO. (2023). Patent landscape reports on kinase inhibitors.
[3] USPTO. (2022). Patent filings related to kinase inhibitors.
[4] Han, X., et al. (2021). Structure and function of kinase inhibitors in cancer therapy. Journal of Medicinal Chemistry, 64(12), 8644–8662.
